Canada: The Requirement Of Causation In An Accounting Of Profits – Federal Court Of Appeal Rules On Availability Of Non-Infringing Alternatives And Apportionment Of Non-Infringing Services

Last Updated: March 28 2017
Article by R. Scott MacKendrick and Anastassia Trifonova

In a recent patent accounting of profits decision of the Federal Court of Appeal in Apotex Inc v ADIR, 2017 FCA 23, the Court emphasized that the profits need to be causally attributable to the invention. The Court also dealt with: 1) the availability of non-infringing alternatives on export sales; and 2) the apportionment of profit from the provision of indemnity and legal services.

The accounting of profits arose from a decision that found that Apotex Inc. and Apotex Pharmachem Inc. (collectively "Apotex") infringed Canadian Patent No. 1,341,196 ("196 Patent"). The 196 Patent covered perindopril and is owned by ADIR, and Servier Canada Inc. was a person claiming under the patentee (collectively "Servier"). Following the liability determination, Servier elected to recover Apotex's profits as a result of Apotex's infringing activities.

On June 18, 2015, Justice Gagné of the Federal Court ordered Apotex to pay to Servier over $61 million dollars in profits attributable to the infringement of the 196 Patent. Justice Gagné considered Apotex's Canadian profits as well as profits from the sale of perindopril tablets abroad, particularly to Apotex's affiliates located in Australia and UK.

The issue for the Federal Court of Appeal was the determination of the profits earned by Apotex on export sales. Specifically, Apotex argued that Justice Gagné erred in failing to consider non-infringing alternatives to the infringing perindopril and in failing to discount profits earned from provision of non-infringing services.

Availability of Non-Infringing Alternatives

At trial, Justice Gagné considered Apotex's assertion that there were "a number of viable, non-infringing alternative sources" of perindopril. However, she rejected Apotex's argument that its profits should be calculated by taking into account the availability of non-infringing perindopril for export sales.

On appeal, the Federal Court of Appeal noted that in Monsanto Canada Inc v Schmeiser, 2004 SCC 34:

 "...the Supreme Court referred to the differential profit approach as the "preferred means" of calculating an accounting of profits – not the only means. However, at bottom is the need to ensure that a patentee only receives that portion of the infringer's profit that is causally attributable to the invention." [emphasis added]

The Federal Court of Appeal accepted Apotex's argument that the value of the invention can "only be quantified if non-infringing alternatives are considered" and held that it was an error not to take into account the availability of non-infringing perindopril for export sales.

The Federal Court of Appeal then analyzed Justice Gagné's assessment of the evidence. In doing so, it endorsed the causation analysis used in Apotex Inc v Merck & Co, Inc, 2015 FCA 171 and Pfizer Canada Inc v Teva Canada Limited, 2016 FCA 161. In those decisions, compensatory damages and damages under section 8 of the Patented Medicines (Notice of Compliance) Regulations, respectively, were being considered. The Federal Court of Appeal held that the damages causation approach used in those decisions had equal application in the context of accounting of profits. For a summary of the Federal Court of Appeal decision in Apotex Inc v Merck & Co, Inc, and its damages causation approach, please see "But for", "Could" and "Would": The Patent Damages Approach to Non-infringing Alternatives. The Federal Court of Appeal concluded that the trial judge failed to adequately consider the evidence as to the ability of Apotex's suppliers to provide non-infringing perindopril and remitted the issue of non-infringing alternatives back to the Federal Court.

Apportionment of Non-Infringing Services

As part of its defence, Apotex also argued that the revenue it received under the transfer price agreements for the sale of perindopril to its affiliates in UK and Australia should be apportioned. Apotex asserted that since perindopril was a "Patent Challenge Product" and carried a heightened risk of litigation, the higher price paid by its UK and Australian affiliates for perindopril was due to the indemnity provision and related litigation services. Justice Gagné rejected this argument and found that the heightened transfer price was due to the sale of the drug itself.

On appeal, the Federal Court of Court concluded that the apportionment would not be appropriate on the facts of this case because, "but for" its infringing activities, Apotex would not have made any profit.

What drove Apotex' sales of perindopril were the new and useful characteristics of the drug. Had perindopril not been protected by the 196 Patent, there would have been no need for Apotex to provide an indemnity to protect the fragility of its affiliates. "But for" the infringing qualities of perindopril, Apotex would have earned nothing on its sale, whether attributable to the drug itself or to the indemnity required to protect the affiliates. Thus, the profit resulting from the sale of perindopril was entirely causally attributable to the invention. It follows that no apportionment is warranted. [emphasis added]

The Federal Court of Appeal held that even though the trial judge committed an extricable error of law in interpreting the contracts between Apotex and its affiliates, the need for a larger price "where the litigation risk loomed large" did not establish that Apotex's affiliates agreed to pay the difference between the Patent Challenge Product price and the non-infringing patent price solely in exchange for Apotex's protection. The Court noted that for any agreement to apportion the revenue in such a way, the agreement "should have precisely set out what was to be paid for what".

In summary, the Federal Court of Appeal's decision reaffirms the settled law that a patentee is only entitled to a portion of the infringer's profit that is causally attributable to the invention when accounting of profits is elected, and this causal attribution requirement bears both on the consideration of non-infringing alternatives and apportionment.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
R. Scott MacKendrick
Anastassia Trifonova
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions